Midgard Science

Reithera

Rome, Italy reithera.com

From their website, Nov 2026

Work here? Claim this listing

About

ReiThera develops and manufactures viral-vector-based genetic vaccines and advanced therapies. It supports biotech and pharmaceutical programs from early research through clinical and commercial readiness, with sites in Rome and Naples, Italy.

Services

  • Technology Development

    Transforms nucleotide or amino acid sequences and early-stage concepts into functional viral vectors for research, pre-GMP development, or GMP manufacturing.

  • Vector engineering

    Designs, engineers, optimizes, and characterizes viral vectors for vaccines and advanced therapies.

  • Plasmid design and sequence assembly

    Provides codon optimization, transgene design, plasmid construction, and sequence assembly for vector programs.

  • Recombinant seed generation

    Creates recombinant seed material for viral vector development.

  • R&D-grade vector production

    Produces vectors at research grade for early development work.

  • Pre-GMP seed production

    Generates seed material intended for pre-GMP development workflows.

  • Analytical method development

    Develops fit-for-purpose analytical methods and customized analytical strategies for vector programs.

  • Process Development

    Designs and optimizes upstream and downstream workflows for scalable viral vector manufacturing.

  • GMP Manufacturing

    Manufactures viral vectors and ATMPs under GMP for clinical development and commercial production.

  • Aseptic fill-finish

    Provides aseptic filling in EC Grade B facilities with automated and manual options.

  • Quality System

    Supports development and manufacturing under an integrated quality system.

  • Analytics

    Provides analytical development integrated with process development, manufacturing, and quality functions.

Turnaround
Rapid vector development

Capabilities

Assays and studies
AAV · Process development · HEK293 · Bioreactors · Fill-finish · Analytical method development · Fit-for-purpose analytical methods · Batch release · In-process control
Scale and capacity
2,000 L bioreactor capacity · 870 m² GMP production suites · 400 m² quality control laboratories · 3,470 m² total area · 1,500 m² newly validated expansion area · Up to 2 L bulk independent small-scale production area · Up to 30 m² cultivation area · Up to 3,500 vials per batch
Therapeutic areas
Infectious diseases · Oncology · Personalized medicine · Cancer immunotherapy

Instruments and platforms

  • 2,000 L bioreactors
  • 200 L disposable stirred-tank bioreactors
  • 1,000 L disposable stirred-tank bioreactors
  • 2,000 L disposable stirred-tank bioreactors
  • Fixed-bed bioreactors
  • WAVE bioreactors
  • oRABS Isolator System
  • Watson-Marlow Flexicon FCP50W Automated Filler

Modalities and species

Modalities
Antibody · Viral vector · Vaccine · Plasmid DNA
Species and models
HEK293 · Duck Embryo Fibroblast-derived production platform · Gorilla adenovirus · Chimpanzee-derived adenovirus (ChAd)

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    As listed: GMP-certified facility; cGMP production suites

Company

Type
CRDMO

Locations

Based in
Rome, Italy
Sites
Rome, Italy · Naples, Italy

Contacts

Public records

Parent company
REITHERA S.R.L. · IT GLEIF

Similar labs

Work here? Claim this listing